Log in

News

  • Home
  • Resources
  • Literature Updates
  • Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

11 Dec 2019 6:04 AM | Anonymous

Charlotte I. Stroes; Sandor Schokker, MD; Aafke Creemers, MD; Remco J. Molenaar, MD, PhD; Maarten C.C.M. Hulshof, MD, PhD; Stephanie O. van der Woude, MD; Roel J. Bennink, MD, PhD; Ron A.A. Mathôt, PharmD, PhD; Kausilia K. Krishnadath, MD, PhD; Cornelis J.A. Punt, MD, PhD; Rob H.A. Verhoeven, PhD; Martijn G.H. van Oijen, PhD; Geert-Jan Creemers, MD, PhD; Grard A.P. Nieuwenhuijzen, MD, PhD; Maurice J.C. van der Sangen, MD, PhD; Laurens V. Beerepoot, MD, PhD; Joos Heisterkamp, MD, PhD; Maartje Los, MD, PhD; Marije Slingerland, MD, PhD; Annemieke Cats, MD, PhD; Geke A.P. Hospers, MD, PhD; Maarten F. Bijlsma, PhD; Mark I. van Berge Henegouwen, MD, PhD; Sybren L. Meijer, MD, PhD; and Hanneke W.M. van Laarhoven, MD, PhD.

Click here to read the full abstract.

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software